MDM2 and cancer: Chou et al25 proposed that AMPK can reverse the mesenchymal phenotype of cancer cells by targeting the Akt‐MDM2‐Foxo3a signaling axis, while Saxena et al26 hold that high level of AMPK was an accelerator of pathological EMT.